Immunotherapy in Gynecologic Cancers: Are We There Yet?

ABSTRACT:

Opinion statement

Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis. This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies. The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research. Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies. Immune checkpoint inhibitors, in particular, hold promising potential in specific subsets of endometrial cancer that express microsatellite instability. The key to successful treatment with immunotherapy involves identification of the subgroup of patients that will d

SUBMITTER: Pakish JB 

PROVIDER: S-EPMC5936621 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature